UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 766

Sortiert nach

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Investigational new drugs, 2014-10, Vol.32 (5), p.825-837

2014

Link zum Volltext

Verfügbarkeit prüfen

Development of artemisinin compounds for cancer treatment

Investigational new drugs, 2013-02, Vol.31 (1), p.230-246

2013

Link zum Volltext

Verfügbarkeit prüfen

Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials

Investigational new drugs, 2013-08, Vol.31 (4), p.1087-1094

2013

Link zum Volltext

Verfügbarkeit prüfen

Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells

Investigational new drugs, 2014-12, Vol.32 (6), p.1053-1062

2014

Link zum Volltext

Verfügbarkeit prüfen

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

Investigational new drugs, 2013-08, Vol.31 (4), p.833-844

2013

Link zum Volltext

Verfügbarkeit prüfen

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines

Investigational new drugs, 2014-10, Vol.32 (5), p.783-794

2014

Link zum Volltext

Verfügbarkeit prüfen

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

Investigational new drugs, 2014-08, Vol.32 (4), p.577-586

2014

Link zum Volltext

Verfügbarkeit prüfen

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

Investigational new drugs, 2014-06, Vol.32 (3), p.436-444

2014

Link zum Volltext

Verfügbarkeit prüfen

Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation

Investigational new drugs, 2014-08, Vol.32 (4), p.604-617

2014

Link zum Volltext

Verfügbarkeit prüfen

Kidney injuries related to ipilimumab

Investigational new drugs, 2014-08, Vol.32 (4), p.769-773

2014

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells

Investigational new drugs, 2014-12, Vol.32 (6), p.1096-1104

2014

Link zum Volltext

Verfügbarkeit prüfen

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors

Investigational new drugs, 2014-12, Vol.32 (6), p.1144-1154

2014

Link zum Volltext

Verfügbarkeit prüfen

Novel antitumour indole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting microtubules

Investigational new drugs, 2014-10, Vol.32 (5), p.838-850

2014

Link zum Volltext

Verfügbarkeit prüfen

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

Investigational new drugs, 2014-10, Vol.32 (5), p.851-859

2014

Link zum Volltext

Verfügbarkeit prüfen

Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer

Investigational new drugs, 2014-10, Vol.32 (5), p.904-912

2014

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

Investigational new drugs, 2013-08, Vol.31 (4), p.949-958

2013

Link zum Volltext

Verfügbarkeit prüfen

Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways

Investigational new drugs, 2013-06, Vol.31 (3), p.545-557

2013

Link zum Volltext

Verfügbarkeit prüfen

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis

Investigational new drugs, 2013-08, Vol.31 (4), p.1078-1086

2013

Link zum Volltext

Verfügbarkeit prüfen

Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells

Investigational new drugs, 2014-02, Vol.32 (1), p.68-74

2014

Link zum Volltext

Verfügbarkeit prüfen

The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein—a well-known, yet poorly understood drug transporter

Investigational new drugs, 2014-08, Vol.32 (4), p.618-625

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

Investigational new drugs, 2013-02, Vol.31 (1), p.77-84

2013

Link zum Volltext

Verfügbarkeit prüfen

Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer

Investigational new drugs, 2013-10, Vol.31 (5), p.1142-1150

2013

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study

Investigational new drugs, 2014-10, Vol.32 (5), p.995-1004

2014

Link zum Volltext

Verfügbarkeit prüfen

Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance

Investigational new drugs, 2014-12, Vol.32 (6), p.1167-1180

2014

Link zum Volltext

Verfügbarkeit prüfen

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines

Investigational new drugs, 2013-04, Vol.31 (2), p.461-468

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 766

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Immunology And Immunotherapy

ThemaAdult

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Zeitschrift / SerieInvestigational New Drugs

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(766)
Mit Volltextzugriff
(766)

Publikationsform

Artikel
(766)

Sprache

Englisch
(766)
Japanisch
(73)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Journals@Ovid Complete
(766)
Springer Nature - Complete Springer Journals
(766)
MEDLINE
(607)
IngentaConnect Journals
(204)

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Development of artemisinin compounds for cancer treatment

Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials

Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation

Kidney injuries related to ipilimumab

Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors

Novel antitumour indole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting microtubules

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis

Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells

The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein—a well-known, yet poorly understood drug transporter

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer

Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study

Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines

Aktive Filter

Suchergebnisse filtern